Tandem Diabetes Care’s revenue trajectory
In its first-quarter earnings conference call, Tandem Diabetes Care (TNDM) increased its fiscal 2019 revenue guidance from $255 million to $271 million to $300 million to $315 million. The older revenue guidance was mainly based on an assumed renewal rate, as well as modest estimates about market expansion and about the conversion of patients still on Animas insulin pumps.
In the first quarter, Tandem Diabetes Care reported revenues of $66 million, a YoY rise of 141.94% and ahead of the consensus estimate by $18.45 million. According to the first quarter earnings conference call, this performance was attributable to renewal orders from the company’s installed base, demand from MDI patients, patients switching from competitors, and the company’s international market expansion strategy. These factors persisted despite the inherent quarterly seasonality in the insulin pump business, associated with resets in deductibles.
Tandem Diabetes Care’s new fiscal 2019 revenue guidance represents YoY growth of 63% to 71% and is based on the expected continuation of the strong revenue momentum reported by the company in the first quarter. The company continues to report robust demand for its t: slim X2 pump both from patients using multiple daily injections of insulin as well as those using competitor insulin pumps.
Analysts expect Tandem Diabetes Care’s revenues to rise YoY by 69.91% to $312.41 million in fiscal 2019, 22.97% to $384.17 million in fiscal 2020, and 20.10% to $461.41 million in fiscal 2021.
Insulet Corp’s revenue trajectory
In its first quarter earnings conference call, Insulet (PODD) has increased its fiscal 2019 revenue guidance from $662 million to $687 million, which represents YoY growth of 17% to 22% to $667 million from $690 million, representing YoY growth of 18% to 22%. The company has guided for $1.0 billion in revenues for fiscal 2021.
In the first quarter, Insulet reported revenues of $159.56 million, a YoY rise of 29.09% and ahead of the consensus estimate by $4.9 million.
Analysts expect Insulet’s revenues to rise YoY by 21.40% to $684.51 million in fiscal 2019, 18.54% to $811.44 million in fiscal 2020, and 21.22% to $983.64 million in fiscal 2021.